RGD With Minimally Invasive Non-Surgical Technique in Treatment of Periodontal Intrabony Defect

Not Applicable

Not yet recruiting

• Conditions: Intrabony Defect; Periodontal Diseases; Alveolar Bone Loss
• Interventions: Drug: RGD Peptide

• Registration Number: NCT06936605
• Lead Sponsor: Minia University

Brief Summary

Periodontal regeneration is a complex process that involves coordinated activities and interactions of many cell types, extracellular matrix, cytokines, and specific growth factors to restore tissue integrity. The most important challenge facing periodontal regeneration is cellular insufficiency. Periodontal defects usually have a limited regenerative capacity due to their bounded surface area which is supposed to provide the wound area with a limited number of viable cells and a limited amount of biologic mediators. Cell recruitment and adhesion into the defect area are essential for cells to survive and secrete collagen.

Apoptosis is initiated when failure in adhesion in many different cell types occurs. Some periodontal treatment options failed in the reconstruction of the defect due to failure in wound stabilization and subsequent cell adhesion. Many treatment options have been developed to enhance defect stability and cellular recruitment including the use of GTM and different biologics. However, the treatment outcomes vary considerably depending on the level of the defect cellularity and the degree of cell recruitment into the defect area. For maximum outcomes, enhanced stability, vascularity, and biologics-sustained delivery were suggested. The minimally invasive surgical technique (MIST) suggested by Cortellini et al. offers a suitable level of tissue preservation that could help in defect stability and cellular adhesion. It was suggested to promote flap stability, maintain space, and maintain a greater amount of blood supply at the alveolar crest and papillary levels.

Detailed Description

Periodontitis is an inflammatory multifactorial disease initiated by pathogenic bacteria accumulated as a biofilm on the tooth surface leading to clinical attachment loss (CAL), pocket formation (PD), bleeding on probing (BOP), and bone loss which if neglected may lead to increased tooth mobility and final tooth loss. Pathological tooth mobility may arise from extensive alveolar bone loss, traumatic occlusion, acute periodontal inflammation, and apical tooth displacement. Treating tooth mobility can be a challenging process, particularly for patients with severe periodontitis, including those in stage III or IV, who often experience a range of these symptoms. ue to compromised periodontal support. Therefore, effective treatment not only relies on periodontal therapy but also on occlusal stability and tooth splinting

Study Timeline

• Status Verified: 2025-01
• Study First Submitted: 2025-04-10
• Study Start: 2025-04-15
• Study First Submitted QC: 2025-04-17
• Last Update Submitted: 2025-04-17
• Study First Posted: 2025-04-20
• Last Update Posted: 2025-04-20
• Primary Completion: 2025-09-20
• Study Completion: 2025-10-20

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• • All patients included will have moderate to advanced periodontitis.

  • Patients included in this study will be free from any systemic diseases according to criteria of Modified Cornell Medical Index(10).
  • Patients who had not undergone any type of regenerative periodontal therapy six months prior to the initial examination.

Exclusion Criteria

• • Patients with systemic diseases, smokers, pregnant (female).

  • Patients received antibiotics or non-steroidal anti-inflammatory drugs six months before the beginning of the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
negative control group	RGD Peptide	Fifteen periodontitis patients will receive Phase I therapy, reevaluation after four weeks with minimally invasive non-surgical technique
control group	RGD Peptide	Fifteen periodontitis patients will receive Phase I therapy, reevaluation after four weeks with minimally invasive non-surgical technique with placebo hydrogel
study group	RGD Peptide	Fifteen periodontitis patients will receive Phase I therapy, reevaluation after four weeks with minimally invasive non-surgical technique with RGD hydrogel

Primary Outcome Measures

Name	Time	Method
CAL by millimeters	baseline, 3months and 6 months	Measure clinical attachment loss pre and after-intervention